TuisKLBF • IDX
add
Kalbe Farma Tbk PT
Vorige sluiting
Rp 1 535,00
Dagwisseling
Rp 1 510,00 - Rp 1 555,00
Jaarwisseling
Rp 985,00 - Rp 1 795,00
Markkapitalisasie
71,62Â bn IDR
Gemiddelde volume
47,91Â m
P/V-verhouding
20,95
Dividend-opbrengs
2,35%
PrimĂŞre beurs
IDX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(IDR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Inkomste | 8,85Â bn | 5,77% |
Bedryfskoste | 2,24Â bn | 9,58% |
Netto inkomste | 1,08Â bn | 12,45% |
Netto winsgrens | 12,17 | 6,29% |
Wins per aandeel | 23,57 | 13,86% |
EBITDA | 1,57Â bn | 11,60% |
Effektiewe belastingkoers | 22,83% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(IDR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 4,69Â bn | 10,74% |
Totale bates | 30,58Â bn | 5,59% |
Totale aanspreeklikheid | 5,22Â bn | 7,63% |
Totale ekwiteit | 25,36 bn | — |
Uitstaande aandele | 45,65 mjd | — |
Prys om te bespreek | 2,98 | — |
Opbrengs op bates | 11,54% | — |
Opbrengs op kapitaal | 13,57% | — |
Kontantvloei
Netto kontantverandering
(IDR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Netto inkomste | 1,08Â bn | 12,45% |
Kontant van bedrywe | 344,56Â mjd | -71,44% |
Kontant van beleggings | -118,66Â mjd | 61,24% |
Kontant van finansiering | -423,13Â mjd | -791,88% |
Netto kontantverandering | -180,46Â mjd | -121,28% |
Beskikbare kontantvloei | -102,67Â mjd | -114,36% |
Meer oor
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Gestig
10 Sep. 1966
Webwerf
Werknemers
12Â 841